LZLinqun Zheng

Linqun Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linqun Zheng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study

    by Jiaqi Shen, Zikan Zhong, Xiaoyu Wu, Tingting Fang, Linqun Zheng, Mei Kang, Yan Zhu, Yu’E Zhang, Yong Wei, Songwen Chen, et al.

    Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.

  • Open Access

    Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study

    by Jiaqi Shen, Zikan Zhong, Xiaoyu Wu, Tingting Fang, Linqun Zheng, Mei Kang, Yan Zhu, Yu’E Zhang, Yong Wei, Songwen Chen, et al.

    Background: Abnormal uterine bleeding is a clinically important but often overlooked concern during antithrombotic therapy, particularly in cardiovascular care where anticoagulant and antiplatelet regimens are used. Objective: To describe paired menstrual changes during cardiovascular antithrombotic therapy and to explore documented increased or prolonged bleeding across treatment classes and observed regimens. Methods: This prospective observational paired clinical follow-up study included 50 menstruating women aged 18–55 years with regular menses who received antithrombotic therapy for cardiovascular conditions. Source records specified monthly follow-up and at least 3 months of anticipated treatment. Primary outcomes were paired changes in menstrual-cycle category and menstrual duration; documented increased or prolonged bleeding and variation across observed regimens were secondary exploratory outcomes. Results: Abnormal menstrual-cycle categories increased from 8/50 (16.0%) to 14/50 (28.0%), and prolonged menses increased from 2/49 (4.1%) to 8/49 (16.3%); both exact McNemar P=0.031. Documented increased or prolonged bleeding was recorded in 17/46 evaluable participants (37.0%). Menstrual-related healthcare use or absence was more frequent among those with documented bleeding than among those without it (9/17 vs 4/29; Fisher P = 0.007). The proportion with documented bleeding varied across seven observed regimens (P=0.006) and was highest among rivaroxaban recipients (13/19, 68.4%). Conclusions: Menstrual changes and bleeding-related clinical burden were observed during follow-up in women receiving antithrombotic therapy for cardiovascular conditions. The proportion with documented bleeding varied across observed regimens and was highest among rivaroxaban recipients. Larger prospective studies using standardized menstrual outcome measures are needed to evaluate between-regimen differences.